| John Maxwell Pike Jr, MD | |
|
3901 Rainbow Blvd, Ms 3405, Kansas City, KS 66160-8500 | |
| (913) 588-7076 | |
| Not Available |
| Full Name | John Maxwell Pike Jr |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 11 Years |
| Location | 3901 Rainbow Blvd, Kansas City, Kansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093159782 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 2018010220 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Adventhealth Shawnee Mission | Shawnee mission, KS | Hospital |
| Adventhealth Ottawa | Ottawa, KS | Hospital |
| North Kansas City Hospital | North kansas city, MO | Hospital |
| New Liberty Hospital District | Liberty, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mawd Pathology Group Pa | 2668421389 | 38 |
| Mawd Pathology Group Pa | 2668421389 | 38 |
News Archive
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced updated clinical data on CAL-101, the Company's oral, delta selective PI3K inhibitor, presented during two oral presentations at the 51st American Society of Hematology Annual Meeting in New Orleans.
The combination of traditional chemotherapy agents with targeted therapies called monoclonal antibodies showed no safety concerns and improved survival in patients with advanced non-small cell lung cancer according to a study presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology, sponsored by ASTRO, ASCO, IASLC and the University of Chicago.
An unfortunate side effect of the platinum-chemotherapy drug oxaliplatin is the development of neurotoxicity, which can adversely affect a patient's quality of life; therefore, the benefit of oxaliplatin-based therapy must be balanced with prevention of neuropathies. Currently, there are no therapeutic interventions available to relieve oxaliplatin-associated neurological symptoms, which are thought to be a result of reactive oxygen species-associated damage.
America's seniors suffer a disproportionate burden of oral disease while having fewer resources for appropriate care - and these issues will be exacerbated as the elderly population grows.
Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, today announced the treatment of its first patient in a multicentre, open, non-comparative Phase III study to investigate the efficacy, safety, and pharmacokinetics of two subcutaneous (SC) injections of Debio 8206 (triptorelin pamoate 22.5 mg 6-month formulation) in patients with advanced prostate cancer.
› Verified 9 days ago
| Entity Name | Mawd Pathology Group Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033108519 PECOS PAC ID: 2668421389 Enrollment ID: O20061024000121 |
News Archive
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced updated clinical data on CAL-101, the Company's oral, delta selective PI3K inhibitor, presented during two oral presentations at the 51st American Society of Hematology Annual Meeting in New Orleans.
The combination of traditional chemotherapy agents with targeted therapies called monoclonal antibodies showed no safety concerns and improved survival in patients with advanced non-small cell lung cancer according to a study presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology, sponsored by ASTRO, ASCO, IASLC and the University of Chicago.
An unfortunate side effect of the platinum-chemotherapy drug oxaliplatin is the development of neurotoxicity, which can adversely affect a patient's quality of life; therefore, the benefit of oxaliplatin-based therapy must be balanced with prevention of neuropathies. Currently, there are no therapeutic interventions available to relieve oxaliplatin-associated neurological symptoms, which are thought to be a result of reactive oxygen species-associated damage.
America's seniors suffer a disproportionate burden of oral disease while having fewer resources for appropriate care - and these issues will be exacerbated as the elderly population grows.
Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, today announced the treatment of its first patient in a multicentre, open, non-comparative Phase III study to investigate the efficacy, safety, and pharmacokinetics of two subcutaneous (SC) injections of Debio 8206 (triptorelin pamoate 22.5 mg 6-month formulation) in patients with advanced prostate cancer.
› Verified 9 days ago
| Entity Name | Mawd Pathology Partners Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508249228 PECOS PAC ID: 7618278771 Enrollment ID: O20151214001703 |
News Archive
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced updated clinical data on CAL-101, the Company's oral, delta selective PI3K inhibitor, presented during two oral presentations at the 51st American Society of Hematology Annual Meeting in New Orleans.
The combination of traditional chemotherapy agents with targeted therapies called monoclonal antibodies showed no safety concerns and improved survival in patients with advanced non-small cell lung cancer according to a study presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology, sponsored by ASTRO, ASCO, IASLC and the University of Chicago.
An unfortunate side effect of the platinum-chemotherapy drug oxaliplatin is the development of neurotoxicity, which can adversely affect a patient's quality of life; therefore, the benefit of oxaliplatin-based therapy must be balanced with prevention of neuropathies. Currently, there are no therapeutic interventions available to relieve oxaliplatin-associated neurological symptoms, which are thought to be a result of reactive oxygen species-associated damage.
America's seniors suffer a disproportionate burden of oral disease while having fewer resources for appropriate care - and these issues will be exacerbated as the elderly population grows.
Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, today announced the treatment of its first patient in a multicentre, open, non-comparative Phase III study to investigate the efficacy, safety, and pharmacokinetics of two subcutaneous (SC) injections of Debio 8206 (triptorelin pamoate 22.5 mg 6-month formulation) in patients with advanced prostate cancer.
› Verified 9 days ago
| Entity Name | Mawd Pathologists, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376209130 PECOS PAC ID: 5193102028 Enrollment ID: O20220517002528 |
News Archive
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced updated clinical data on CAL-101, the Company's oral, delta selective PI3K inhibitor, presented during two oral presentations at the 51st American Society of Hematology Annual Meeting in New Orleans.
The combination of traditional chemotherapy agents with targeted therapies called monoclonal antibodies showed no safety concerns and improved survival in patients with advanced non-small cell lung cancer according to a study presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology, sponsored by ASTRO, ASCO, IASLC and the University of Chicago.
An unfortunate side effect of the platinum-chemotherapy drug oxaliplatin is the development of neurotoxicity, which can adversely affect a patient's quality of life; therefore, the benefit of oxaliplatin-based therapy must be balanced with prevention of neuropathies. Currently, there are no therapeutic interventions available to relieve oxaliplatin-associated neurological symptoms, which are thought to be a result of reactive oxygen species-associated damage.
America's seniors suffer a disproportionate burden of oral disease while having fewer resources for appropriate care - and these issues will be exacerbated as the elderly population grows.
Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, today announced the treatment of its first patient in a multicentre, open, non-comparative Phase III study to investigate the efficacy, safety, and pharmacokinetics of two subcutaneous (SC) injections of Debio 8206 (triptorelin pamoate 22.5 mg 6-month formulation) in patients with advanced prostate cancer.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John Maxwell Pike Jr, MD 604 Lake Shore Dr, Goldsboro, NC 27534-8970 Ph: (919) 738-8771 | John Maxwell Pike Jr, MD 3901 Rainbow Blvd, Ms 3405, Kansas City, KS 66160-8500 Ph: (913) 588-7076 |
News Archive
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced updated clinical data on CAL-101, the Company's oral, delta selective PI3K inhibitor, presented during two oral presentations at the 51st American Society of Hematology Annual Meeting in New Orleans.
The combination of traditional chemotherapy agents with targeted therapies called monoclonal antibodies showed no safety concerns and improved survival in patients with advanced non-small cell lung cancer according to a study presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology, sponsored by ASTRO, ASCO, IASLC and the University of Chicago.
An unfortunate side effect of the platinum-chemotherapy drug oxaliplatin is the development of neurotoxicity, which can adversely affect a patient's quality of life; therefore, the benefit of oxaliplatin-based therapy must be balanced with prevention of neuropathies. Currently, there are no therapeutic interventions available to relieve oxaliplatin-associated neurological symptoms, which are thought to be a result of reactive oxygen species-associated damage.
America's seniors suffer a disproportionate burden of oral disease while having fewer resources for appropriate care - and these issues will be exacerbated as the elderly population grows.
Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, today announced the treatment of its first patient in a multicentre, open, non-comparative Phase III study to investigate the efficacy, safety, and pharmacokinetics of two subcutaneous (SC) injections of Debio 8206 (triptorelin pamoate 22.5 mg 6-month formulation) in patients with advanced prostate cancer.
› Verified 9 days ago
Dr. Mark T Cunningham, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd, Dept Of Pathology, Kansas City, KS 66160 Phone: 913-588-7070 Fax: 913-588-7073 | |
Anders Meyer, Pathology Medicare: Accepting Medicare Assignments Practice Location: 4000 Cambridge St, Kansas City, KS 66160 Phone: 913-588-7090 | |
Christopher Jurief, DO Pathology Medicare: Medicare Enrolled Practice Location: 3901 Rainbow Blvd, Kansas City, KS 66160 Phone: 913-945-7972 | |
Dr. Diane L Persons, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 3901 Rainbow Blvd, Dept Of Pathology, Kansas City, KS 66160 Phone: 913-588-7070 Fax: 913-588-7073 | |
Dr. Zhan Ye, M.D., PH.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 4000 Cambridge St, Kansas City, KS 66160 Phone: 913-588-1651 | |
Dr. Kathy L Newell, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd, Dept Of Pathology, Kansas City, KS 66160 Phone: 913-588-7070 Fax: 913-588-7073 | |
Maura Frances O'neil, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 4000 Cambridge St, Kansas City, KS 66160 Phone: 913-588-7073 Fax: 913-588-7073 |